Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 2/20 | 0.32 |
| ▸ | GPR52 | Q9Y2T5 | 6/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31161755 | 0.93 | UCHL1 (0.34) | PDE1BGPR52 | |
| SCHEMBL31161405 | 0.92 | F10 (0.36) | PDE1BGPR52ROCK1 | |
| SCHEMBL30391637 | 0.90 | TYK2 (0.33) | ROCK1 | |
| SCHEMBL26099972 | 0.90 | TYK2 (0.33) | ROCK1 | |
| SCHEMBL31161617 | 0.90 | F10 (0.33) | ROCK1 | |
| SCHEMBL31161283 | 0.90 | F10 (0.33) | ROCK1 | |
| SCHEMBL31161740 | 0.90 | GPR52 (0.32) | PDE1BGPR52 | |
| SCHEMBL31161517 | 0.89 | TYK2 (0.33) | PDE1B | |
| SCHEMBL31161354 | 0.84 | F10 (0.36) | GPR52ROCK1 | |
| SCHEMBL30392359 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2024220937-A2 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | PDE1B 3074/4885GPR52 3104/4885ROCK1 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.